

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611hxl

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Jun 03	New e-mail delivery for search results now available
NEWS	4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	7	Sep 03	JAPIO has been reloaded and enhanced
NEWS	8	Sep 16	Experimental properties added to the REGISTRY file
NEWS	9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	11	Oct 24	BEILSTEIN adds new search fields
NEWS	12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	13	Nov 18	DKILIT has been renamed APOLLIT
NEWS	14	Nov 25	More calculated properties added to REGISTRY
NEWS	15	Dec 04	CSA files on STN
NEWS	16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	17	Dec 17	TOXCENTER enhanced with additional content
NEWS	18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	20	Feb 13	CANCERLIT is no longer being updated
NEWS	21	Feb 24	METADEX enhancements
NEWS	22	Feb 24	PCTGEN now available on STN
NEWS	23	Feb 24	TEMA now available on STN
NEWS	24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	25	Feb 26	PCTFULL now contains images
NEWS	26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	27	Mar 20	EVENTLINE will be removed from STN
NEWS	28	Mar 24	PATDPAFULL now available on STN
NEWS	29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	30	Apr 11	Display formats in DGENE enhanced
NEWS	31	Apr 14	MEDLINE Reload
NEWS	32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS	34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	35	Apr 28	RDISCLOSURE now available on STN
NEWS	36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	39	May 16	CHEMREACT will be removed from STN

NEWS 40 May 19 Simultaneous left and right truncation added to WSCA
NEWS 41 May 19 RAPRA enhanced with new search field, simultaneous left and
right truncation
NEWS 42 Jun 02 Simultaneous left and right truncation added to CBNB

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:22:01 ON 02 JUN 2003

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:22:13 ON 02 JUN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 JUN 2003 HIGHEST RN 523977-56-2

DICTIONARY FILE UPDATES: 1 JUN 2003 HIGHEST RN 523977-56-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.


Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

Uploading 09840503.str

L1 STRUCTURE UPLOADED

=> d l1
 L1 HAS NO ANSWERS
 L1 STR



G1 CN,Hy
 G2 C,Cy

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
 FULL SEARCH INITIATED 14:22:39 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 302448 TO ITERATE

100.0% PROCESSED 302448 ITERATIONS 234 ANSWERS
 SEARCH TIME: 00.00.06

L2 234 SEA SSS FUL L1

=> fil caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	148.15	148.36

FILE 'CAPLUS' ENTERED AT 14:22:50 ON 02 JUN 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Jun 2003 VOL 138 ISS 23
 FILE LAST UPDATED: 1 Jun 2003 (20030601/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 30 L2

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.25	149.61

FILE 'REGISTRY' ENTERED AT 14:24:49 ON 02 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 JUN 2003 HIGHEST RN 523977-56-2
DICTIONARY FILE UPDATES: 1 JUN 2003 HIGHEST RN 523977-56-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>
Uploading 09840503.str

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR



Hy¹
 G1 CN, [01]
 G2 C, Cy

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 14:25:13 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 15057 TO ITERATE

6.6% PROCESSED 1000 ITERATIONS 1 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 293800 TO 308480
 PROJECTED ANSWERS: 69 TO 533

L5 1 SEA SSS SAM L1

=> s l4

SAMPLE SEARCH INITIATED 14:25:22 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 15057 TO ITERATE

6.6% PROCESSED 1000 ITERATIONS 1 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 293800 TO 308480
 PROJECTED ANSWERS: 69 TO 533

L6 1 SEA SSS SAM L4

06/02/2003


09840503.trn

=> d scan

06/02/2003

09840503.trn

L6 1 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN 4(1H)-Quinolinone, 7-methoxy-2-(4-methylphenyl)-6-(5-oxazolyl)- (9CI)
MF C20 H16 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

06/02/2003

09840503.trn

=> s l4 ful sub=l2

FULL SUBSET SEARCH INITIATED 14:25:40 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 234 TO ITERATE

100.0% PROCESSED 234 ITERATIONS 200 ANSWERS
SEARCH TIME: 00.00.01

L7 200 SEA SUB=L2 SSS FUL L4

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	35.70	185.31

FILE 'CAPLUS' ENTERED AT 14:25:48 ON 02 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Jun 2003 VOL 138 ISS 23
FILE LAST UPDATED: 1 Jun 2003 (20030601/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l7


L8 11 L7

=> d abs ibib hitstr 1-

YOU HAVE REQUESTED DATA FROM 11 ANSWERS - CONTINUE? Y/(N):y

~~L8~~
GI

ANSWER 1 OF 11 CAPLUS COPYRIGHT 2003 ACS



AB Quinolone derivs. I are described [wherein: X = O or S; R¹ = aliph., cycloaliph., or cycloalkylalkyl; R² = cyano or (un)substituted heteroarom.; R³ = H, alkyl, cyano, CO₂H, CO₂R⁶, or CONR⁷R⁸; R⁴ = Alk¹-L¹-Alk²-R⁹; R⁵ = H or alkyl; or NR⁴R⁵ = (un)substituted heterocycloaliph. ring optionally fused to (un)substituted monocyclic C 6-12 arom. group or (un)substituted monocyclic C₁-9 heteroarom.; R⁶ = alkyl; R⁷, R⁸ = H, alkyl; Alk¹ = bond or (un)substituted aliph. chain; L¹ = bond, linker atom or group; Alk² = bond or C₁-3 alkylene chain; R⁹ = H, (un)substituted (hetero)cycloaliph. or (hetero)arom.; provided that R⁴ .noteq. H, and with 2 excluded compds.; including salts, solvates, hydrates, tautomers, isomers, or N-oxides]. The compds. are potent inhibitors of IMP dehydrogenase (IMPDH), and are of use as immunosuppressants, anti-cancer agents, anti-inflammatory agents, antipsoriatics, and anti-viral agents. Synthetic examples include 67 invention compds. (7 claimed) and 41 intermediates. For instance, condensation of the ketene dithioacetal 5-[bis(methylsulfanyl)methylene]-2,2-dimethyl-[1,3]dioxane-4,6-dione, first with 3-methoxy-4-(oxazol-5-yl)aniline in refluxing EtOH (83%), then with indoline using HgCl₂ (82%), gave the vicinal diamine intermediate II. This compd. was thermally cyclized by refluxing in di-Ph ether, to give 57% III, a specifically claimed compd. When assayed against IMPDH-catalyzed, NAD-dependent oxidn. of IMP in vitro, or in a human PMBC (peripheral blood mononuclear cell) proliferation assay, I had IC₅₀ values of 5 .mu.M or below (no addnl. data).

ACCESSION NUMBER: 2003:334904 CAPLUS
DOCUMENT NUMBER: 138:353840
TITLE: 2-Aminoquinolone derivatives for use as IMPDH inhibitors
INVENTOR(S): Haughan, Alan Findlay; Dyke, Hazel Joan; Buckley,

George Martin; Davies, Natasha; Hannah, Duncan Robert;
 Richard, Marianna Dilani; Sharpe, Andrew; Williams,
 Sophie Caroline
 PATENT ASSIGNEE(S): Celltech R & D Limited, UK
 SOURCE: PCT Int. Appl., 78 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035066	A1	20030501	WO 2002-GB4754	20021022
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: GB 2001-25365 A 20011023
 GB 2002-5372 A 20020307

IT 519052-60-9P, 4-[7-Methoxy-6-(oxazol-5-yl)-4-oxo-1,4-dihydroquinolin-2-yl]piperazine-1-carboxylic acid tert-butyl ester
 519052-67-6P, 1-[7-Methoxy-6-(oxazol-5-yl)-4-oxo-1,4-dihydroquinolin-2-yl]piperidine-4-carboxylic acid methyl ester
 519052-74-5P, 7-Methoxy-6-(oxazol-5-yl)-2-(2-oxopyrrolidin-1-yl)-1H-quinolin-4-one 519053-04-4P, 7-Methoxy-6-(oxazol-5-yl)-2-(piperazin-1-yl)-1H-quinolin-4-one dihydrochloride
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; prepn. of aminoquinolone derivs. as IMPDH inhibitors)


RN 519052-60-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 519052-67-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 519052-74-5 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(2-oxo-1-pyrrolidinyl)-
(9CI) (CA INDEX NAME)



RN 519053-04-4 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(1-piperazinyl)-,
dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

IT 519052-55-2P, 7-Methoxy-2-(morpholin-4-yl)-6-(oxazol-5-yl)-1H-quinolin-4-one 519052-65-4P, 2-(2,3-Dihydroindol-1-yl)-7-methoxy-6-(oxazol-5-yl)-1H-quinolin-4-one 519052-77-8P, 7-Methoxy-2-(2-methylpyrrolidin-1-yl)-6-(oxazol-5-yl)-1H-quinolin-4-one 519052-78-9P, 1-(7-Methoxy-6-(oxazol-5-yl)-4-oxo-1,4-dihydroquinolin-2-yl)piperidine-4-carboxylic acid amide 519052-79-0P, 7-Methoxy-6-(oxazol-5-yl)-2-[4-(pyrrolidin-1-yl)piperidin-1-yl]-1H-quinolin-4-one 519052-81-4P, 2-(3,4-Dihydro-1H-isoquinolin-2-yl)-7-methoxy-6-(oxazol-5-yl)-1H-quinolin-4-one 519052-87-0P, 2-(1,3-Dihydroisoindol-2-yl)-7-methoxy-6-(oxazol-5-yl)-1H-quinolin-4-one 519052-91-6P, 2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-7-methoxy-6-(oxazol-5-yl)-1H-quinolin-4-one 519052-92-7P, 2-(5-Bromo-2,3-dihydroindol-1-yl)-7-methoxy-6-(oxazol-5-yl)-1H-quinolin-4-one 519053-00-0P, 7-Methoxy-6-(oxazol-5-yl)-2-(4-phenylpiperidin-1-yl)-1H-quinolin-4-one

519053-02-2P, 7-Methoxy-2-(2-methyl-2,3-dihydroindol-1-yl)-6-(oxazol-5-yl)-1H-quinolin-4-one **519053-05-5P**,
 2-(4-Acetylpiperazin-1-yl)-7-methoxy-6-(oxazol-5-yl)-1H-quinolin-4-one
519053-07-7P, 3-[4-[7-Methoxy-6-(oxazol-5-yl)-4-oxo-1,4-dihydroquinolin-2-yl]piperazin-1-yl]propanoic acid methyl ester formate salt **519053-09-9P**, 2-[4-(2,2-Dimethylpropyl)piperazin-1-yl]-7-methoxy-6-(oxazol-5-yl)-1H-quinolin-4-one formate **519053-11-3P**,
 7-Methoxy-6-(oxazol-5-yl)-2-[4-(pyridin-3-ylmethyl)piperazin-1-yl]-1H-quinolin-4-one formate **519053-12-4P**, 2-(Azetidin-1-yl)-7-methoxy-6-(oxazol-5-yl)-1H-quinolin-4-one **519053-13-5P**,
 7-Methoxy-6-(oxazol-5-yl)-2-(piperidin-1-yl)-1H-quinolin-4-one **519053-14-6P**, 7-Methoxy-2-[(S)-2-(methoxymethyl)pyrrolidin-1-yl]-6-(oxazol-5-yl)-1H-quinolin-4-one **519053-16-8P**,
 7'-Methoxy-6'-(oxazol-5-yl)-3,4-dihydro-2H,1'H-[1,2']-biquinolinyl-4'-one **519053-18-0P**, 7-Methoxy-6-(oxazol-5-yl)-2-(pyrrolidin-1-yl)-1H-quinolin-4-one **519053-20-4P**, 1-[7-Methoxy-6-(oxazol-5-yl)-4-oxo-1,4-dihydroquinolin-2-yl]piperidine-4-carboxylic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prepn. of aminoquinolone derivs. as IMPDH inhibitors)


RN 519052-55-2 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-(4-morpholinyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 519052-65-4 CAPLUS

CN 4(1H)-Quinolinone, 2-(2,3-dihydro-1H-indol-1-yl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 519052-77-8 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-(2-methyl-1-pyrrolidinyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 519052-78-9 CAPLUS

CN 4-Piperidinecarboxamide, 1-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]- (9CI) (CA INDEX NAME)




RN 519052-79-0 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-[4-(1-pyrrolidinyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 519052-81-4 CAPLUS

CN 4(1H)-Quinolinone, 2-(3,4-dihydro-2(1H)-isoquinolinyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 519052-87-0 CAPLUS

CN 4(1H)-Quinolinone, 2-(1,3-dihydro-2H-isoindol-2-yl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 519052-91-6 CAPLUS

CN 4(1H)-Quinolinone, 2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 519052-92-7 CAPLUS

CN 4(1H)-Quinolinone, 2-(5-bromo-2,3-dihydro-1H-indol-1-yl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 519053-00-0 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(4-phenyl-1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 519053-02-2 CAPLUS

CN 4(1H)-Quinolinone, 2-(2,3-dihydro-2-methyl-1H-indol-1-yl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 519053-05-5 CAPLUS

CN Piperazine, 1-acetyl-4-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinoliny]- (9CI) (CA INDEX NAME)




RN 519053-07-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 519053-06-6


CMF C21 H24 N4 O5



CM 2

CRN 64-18-6

CMF C H2 O2



RN 519053-09-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


06/02/2003

09840503.trn

CM 1

CRN 519053-08-8


CMF C22 H28 N4 O3



CM 2

CRN 64-18-6

CMF C H2 O2




RN 519053-11-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 519053-10-2

CMF C23 H23 N5 O3



CM 2


CRN 64-18-6

CMF C H2 O2




RN 519053-12-4 CAPLUS

CN 4(1H)-Quinolinone, 2-(1-azetidiny)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 519053-13-5 CAPLUS


CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 519053-14-6 CAPLUS


CN 4(1H)-Quinolinone, 7-methoxy-2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 519053-16-8 CAPLUS

CN [1(2H),2'-Biquinolin]-4'(1'H)-one, 3,4-dihydro-7'-methoxy-6'-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 519053-18-0 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

09840503.trn

COC1=C2C(=C1)C(=C3C(=C2)C(=O)N(C3)C4CCCC4)C5=CC=CN=C5


CN 4-Piperidinecarboxylic acid, 1-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]- (9CI) (CA INDEX NAME)



5

Page 18

L8 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2003 ACS
GI



applicant

AB Title compds. I [wherein X1 = CO, SO, or SO₂; X2 = CR₃ or N; X3 = NH, O, or S; X4 = CR₄ or N; X5 = CR₅ or N; X6 = CR₆ or N] were prepd. were prepd. as inosine monophosphate dehydrogenase (IMPDH) enzyme inhibitors. For example, acetalization of 4-nitro-2-methoxytoluene with AcOH (51%), redn. to the aldehyde (91%), and cycloaddn. with (p-tolylsulfonyl)methyl isocyanate gave 5-(4-nitro-2-methoxyphenyl)oxazole (84%), which was reduced to the amine (95%). Alkylation with Et benzoylacetate and cyclization afforded the 6-(5-oxazolyl)-4(1H)-quinolinone II. Thus, I are useful as therapeutic agents for IMPDH-assocd. disorders, such as allograft rejection (no data).

ACCESSION NUMBER: 2001:798220 CAPLUS
DOCUMENT NUMBER: 135:344472
TITLE: Preparation of 6-(5-oxazolyl)-4(1H)-quinolinones as inhibitors of IMPDH enzyme
INVENTOR(S): Iwanowicz, Edwin J.; Watterson, Scott H.; Dhar, T. G. Murali; Pitts, William J.; Gu, Henry H.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 263 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081340	A2	20011101	WO 2001-US12900	20010419
WO 2001081340	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1276739	A2	20030122	EP 2001-928708	20010419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002040022	A1	20020404	US 2001-840503	20010423
PRIORITY APPLN. INFO.: US 2000-199420P P 20000424				
WO 2001-US12900 W 20010419				

OTHER SOURCE(S): MARPAT 135:344472
IT 371252-10-7P, 2-[2,3-Dihydro-3-(methylanino)-1H-inden-5-yl]-7-


methoxy-6-(5-oxazolyl)-4(1H)-quinolinone hydrochloride

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)

RN 371252-10-7 CAPLUS

CN 4(1H)-Quinolinone, 2-[2,3-dihydro-3-(methylamino)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


IT 371249-67-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 6-(5-oxazolyl)-4(1H)-quinolinones as inhibitors of IMPDH enzyme)

RN 371249-67-1 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-phenyl- (9CI) (CA INDEX NAME)




IT 371249-88-6P, 2-[2,3-Dihydro-3-(dimethylamino)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)


RN 371249-88-6 CAPLUS

CN 4(1H)-Quinolinone, 2-[3-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




IT **371251-98-8P**, (R)-2-[3-(Dimethylamino)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-99-9P**, (S)-2-[3-(Dimethylamino)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)
 RN 371251-98-8 CAPLUS
 CN 4(1H)-Quinolinone, 2-[(3R)-3-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 371251-99-9 CAPLUS
 CN 4(1H)-Quinolinone, 2-[(3S)-3-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **371249-69-3P 371249-72-8P 371249-75-1P 371249-77-3P 371249-80-8P**, 3-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]benzoic acid methyl ester
371249-84-2P, 2-[3-(Hydroxymethyl)phenyl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371249-85-3P**, 2-[3-(1-Hydroxy-1-

methylethyl)phenyl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone
371249-86-4P, 7-Methoxy-2-[3-(4-methyl-1-piperazinyl)phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone 371249-91-1P, 7-Methoxy-2-[3-(4-methyl-1-piperazinyl)phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone trifluoroacetic acid salt 371249-93-3P, 2-(2,3-Dihydro-3-methoxy-1H-inden-5-yl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone
371249-97-7P 371249-98-8P 371249-99-9P
371250-00-9P 371250-01-0P 371250-03-2P
371250-04-3P 371250-05-4P 371250-06-5P
371250-07-6P 371250-09-8P 371250-11-2P
371250-12-3P 371250-14-5P 371250-15-6P
371250-16-7P 371250-17-8P 371250-18-9P
371250-20-3P 371250-22-5P 371250-23-6P
371250-25-8P 371250-27-0P 371250-29-2P
371250-31-6P 371250-33-8P 371250-35-0P
371250-37-2P 371250-39-4P 371250-41-8P
371250-43-0P 371250-45-2P 371250-47-4P
371250-48-5P 371250-49-6P 371250-50-9P
371250-51-0P 371250-52-1P 371250-53-2P
371250-54-3P 371250-55-4P 371250-56-5P
371250-57-6P 371250-58-7P, 7-Methoxy-2-[3-[(4-methoxyphenyl)methoxy]phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone
371250-59-8P, 2-(3-Hydroxyphenyl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371250-60-1P, 2-[3-[2-(Dimethylamino)ethoxy]phenyl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371250-61-2P,
2-(2,3-Dihydro-2-methyl-1H-isoindol-5-yl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371250-62-3P 371250-63-4P
371250-64-5P 371250-65-6P 371250-66-7P
371250-67-8P 371250-68-9P 371250-69-0P
371250-70-3P 371250-71-4P 371250-72-5P
371250-73-6P 371250-74-7P 371250-75-8P
371250-76-9P 371250-77-0P 371250-78-1P
371250-79-2P 371250-80-5P 371250-81-6P
371250-82-7P 371250-83-8P 371250-84-9P
371250-85-0P 371250-86-1P 371250-87-2P
371250-88-3P 371250-89-4P 371250-90-7P
371250-91-8P 371250-92-9P 371250-93-0P
371250-94-1P 371250-95-2P 371250-96-3P
371250-97-4P 371250-98-5P 371250-99-6P
371251-00-2P 371251-01-3P 371251-02-4P
371251-03-5P 371251-04-6P 371251-05-7P
371251-06-8P 371251-12-6P, 2-[2,3-Dihydro-3-(methylamino)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone
371251-13-7P, 2-[2,3-Dihydro-3-(1-pyrrolidinyl)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371251-16-0P,
2-[2,3-Dihydro-3-(4-morpholinyl)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371251-19-3P, 2-[3-(1-Azetidinyl)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone
371251-21-7P, 7-Methoxy-2-[(3-methylphenyl)methyl]-6-(5-oxazolyl)-4(1H)-quinolinone 371251-29-5P, 7-Methoxy-2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone
371251-36-4P, 3-Hydroxy-7-methoxy-6-(5-oxazolyl)-2-phenyl-4(1H)-quinolinone 371251-40-0P, 3-Hydroxy-7-methoxy-2-(2-methylphenyl)-6-(5-oxazolyl)-4(1H)-quinolinone 371251-41-1P,
3-Hydroxy-7-methoxy-2-(3-methylphenyl)-6-(5-oxazolyl)-4(1H)-quinolinone 371251-42-2P, 3-Hydroxy-7-methoxy-2-(4-methylphenyl)-6-(5-oxazolyl)-4(1H)-quinolinone 371251-43-3P, 2-(3,4-Dimethylphenyl)-3-hydroxy-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone 371251-44-4P
, 3-Hydroxy-7-methoxy-2-(4-methoxyphenyl)-6-(5-oxazolyl)-4(1H)-quinolinone 371251-45-5P, 2-(4-Chloro-3-methylphenyl)-3-hydroxy-7-methoxy-6-(5-

oxazolyl)-4(1H)-quinolinone **371251-47-7P**, 2-(4-Chloro-3-methylphenyl)-3-hydroxy-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone trifluoroacetate **371251-48-8P**, 2-(2,3-Dihydro-3-methoxy-1H-inden-5-yl)-3-hydroxy-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-50-2P**, 3-Hydroxy-7-methoxy-2-[2-(methylsulfonyl)phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone **371251-51-3P**, 2-[1-(Dimethylamino)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-53-5P**, 2-(2,3-Dihydro-3-methoxy-2,2-dimethyl-1H-inden-5-yl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-55-7P**, 2-(2,3-Dihydro-3-methoxy-1,1-dimethyl-1H-inden-5-yl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-57-9P**, trans-2-[3-(Dimethylamino)-2,3-dihydro-2-methoxy-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-60-4P**, trans-2-[3-(Dimethylamino)-2,3-dihydro-2-hydroxy-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-61-5P**, trans-6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-ol methylcarbamate **371251-62-6P**, Ethylcarbamic acid trans-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester **371251-63-7P**, (1-Methylethyl)carbamic acid trans-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester **371251-64-8P**, (2-Chloroethyl)carbamic acid trans-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester **371251-65-9P**, Imidodicarbonic acid trans-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl methyl ester **371251-66-0P**, 7-Methoxy-2-[4-methyl-3-(phenylmethoxy)phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone **371251-68-2P**, 2-(3-Hydroxy-4-methylphenyl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-70-6P**, 7-Methoxy-2-[3-(2-methoxyethoxy)-4-methylphenyl]-6-(5-oxazolyl)-4(1H)-quinolinone **371251-72-8P**, 7-Methoxy-2-[4-methyl-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone **371251-73-9P 371251-74-0P 371251-75-1P 371251-76-2P 371251-77-3P 371251-78-4P 371251-79-5P 371251-80-8P 371251-81-9P 371251-82-0P**, 6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-N,N,N-trimethyl-1H-inden-1-aminium **371251-83-1P**, 2-[3-(Dimethylamino)-2,3-dihydro-1H-inden-5-yl]-3-hydroxy-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-86-4P**, 1,4-Dihydro-3-hydroxy-7-methoxy-2-(4-methylphenyl)-4-oxo-6-quinolinecarbonitrile **371251-88-6P**, 1,4-Dihydro-3-hydroxy-7-methoxy-2-(3-methylphenyl)-4-oxo-6-quinolinecarbonitrile **371251-92-2P**, 2-(2,3-Dihydro-3-hydroxy-1H-inden-5-yl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-94-4P**, 2-(3,4-Dimethoxyphenyl)-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371251-97-7P**, 2-[5-[(Dimethylamino)methyl]-3-thienyl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone **371252-06-1P 371252-09-4P**, N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methylacetamide **371252-11-8P**, N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-2-methoxy-N-methylacetamide **371252-12-9P**, N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl-1H-imidazol-1-acetamide **371252-13-0P**, N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl-4-morpholineacetamide **371252-14-1P**, N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl-2H-1,2,3-triazol-2-acetamide **371252-15-2P**, N-[6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl-1H-1,2,3-triazol-1-acetamide


371252-16-3P 371252-17-4P, Dimethylcarbamic acid
 6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl ester **371252-18-5P**, 2-[2,3-Dihydro-1-(1-pyrrolidinyl)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-4(1H)-quinolinone
371252-19-6P, 4-Acetyl-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-3,4-dihydro-2H-1,4-benzoxazine **371252-21-0P**,
 7-Methoxy-2-[4-(4-morpholinylmethyl)phenyl]-6-(5-oxazolyl)-4(1H)-quinolinone **371252-22-1P**, 6-[1,4-Dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-N,N,N-trimethyl-1H-inden-1-aminium iodide

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of oxazolylquinolinones as inhibitors of IMPDH enzyme for treatment of transplant rejection and other IMPDH-assocd. disorders)


RN 371249-69-3 CAPLUS

CN 4(1H)-Quinolinone, 2-(3-bromophenyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371249-72-8 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-[3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 371249-75-1 CAPLUS


CN 4(1H)-Quinolinone, 7-methoxy-2-(4-methylphenyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371249-77-3 CAPLUS


CN Benzeneacetic acid, 3-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-

quinolinyl]- (9CI) (CA INDEX NAME)




RN 371249-80-8 CAPLUS

CN Benzoic acid, 3-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 371249-84-2 CAPLUS

CN 4(1H)-Quinolinone, 2-[3-(hydroxymethyl)phenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371249-85-3 CAPLUS

CN 4(1H)-Quinolinone, 2-[3-(1-hydroxy-1-methylethyl)phenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371249-86-4 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[3-(4-methyl-1-piperazinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371249-91-1 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[3-(4-methyl-1-piperazinyl)phenyl]-6-(5-oxazolyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 371249-86-4


CMF C24 H24 N4 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 371249-93-3 CAPLUS

CN 4(1H)-Quinolinone, 2-(2,3-dihydro-3-methoxy-1H-inden-5-yl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371249-97-7 CAPLUS

CN 4(1H)-Quinolinone, 2-(3-furanyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA
INDEX NAME)




RN 371249-98-8 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-(3-methylphenyl)-6-(5-oxazolyl)- (9CI) (CA
INDEX NAME)




RN 371249-99-9 CAPLUS

CN 4(1H)-Quinolinone, 2-(2-fluorophenyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA
INDEX NAME)




RN 371250-00-9 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-methyl-6-(5-oxazolyl)- (9CI) (CA INDEX
NAME)




RN 371250-01-0 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-3-methyl-6-(5-oxazolyl)-2-phenyl- (9CI) (CA
INDEX NAME)




RN 371250-03-2 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(2-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 371250-04-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 371250-05-4 CAPLUS

CN Acetamide, N-[3-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]phenyl]-2-hydroxy-N-methyl- (9CI) (CA INDEX NAME)




RN 371250-06-5 CAPLUS

CN Acetamide, 2-(acetyloxy)-N-[3-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 371250-07-6 CAPLUS

CN 4-Morpholineacetamide, N-[3-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 371250-09-8 CAPLUS

CN Benzoic acid, 4-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 371250-11-2 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-(4-methoxyphenyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-12-3 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 371250-14-5 CAPLUS

CN 2-Quinolinepropanamide, N,N-diethyl-1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 371250-15-6 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 371250-16-7 CAPLUS

CN 4(1H)-Quinolinone, 2-(4-hydroxyphenyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-17-8 CAPLUS

CN 4(1H)-Quinolinone, 2-(3,4-dimethylphenyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-18-9 CAPLUS

CN Benzenebutanoic acid, 4-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 371250-20-3 CAPLUS

CN Benzenebutanoic acid, 4-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]- (9CI) (CA INDEX NAME)




RN 371250-22-5 CAPLUS

CN Benzenecetic acid, 4-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]- (9CI) (CA INDEX NAME)




RN 371250-23-6 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(3-thienyl)- (9CI) (CA INDEX NAME)




RN 371250-25-8 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 371250-27-0 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[3-(4-morpholinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-29-2 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-(2-methylphenyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-31-6 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-[3-(1-piperidiny)phenyl]- (9CI) (CA INDEX NAME)




RN 371250-33-8 CAPLUS

CN 4(1H)-Quinolinone, 2-[3-[(dimethylamino)methyl]phenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-35-0 CAPLUS

CN 4(1H)-Quinolinone, 3-bromo-2-[3-[(dimethylamino)methyl]phenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-37-2 CAPLUS

CN Benzenepropanoic acid, 3-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]- (9CI) (CA INDEX NAME)




RN 371250-39-4 CAPLUS

CN 4(1H)-Quinolinone, 2-(2-hydroxyethyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-41-8 CAPLUS

CN 4(1H)-Quinolinone, 2-[(dimethylamino)methyl]-7-methoxy-6-(5-oxazolyl)-
(9CI) (CA INDEX NAME)




RN 371250-43-0 CAPLUS

CN 4(1H)-Quinolinone, 2-(3-hydroxypropyl)-7-methoxy-6-(5-oxazolyl)- (9CI)
(CA INDEX NAME)




RN 371250-45-2 CAPLUS

CN 4(1H)-Quinolinone, 2-(4-hydroxybutyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA
INDEX NAME)




RN 371250-47-4 CAPLUS

CN 4(1H)-Quinolinone, 2-(hydroxymethyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA
INDEX NAME)




RN 371250-48-5 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-(methoxymethyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-49-6 CAPLUS

CN 4(1H)-Quinolinone, 2-(2-hydroxypropyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-50-9 CAPLUS

CN Benzenesulfonamide, 4-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]- (9CI) (CA INDEX NAME)




RN 371250-51-0 CAPLUS

CN 4(1H)-Quinolinone, 2-(hydroxyphenylmethyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-52-1 CAPLUS

CN 4(1H)-Quinolinone, 2-(1-hydroxyethyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-53-2 CAPLUS


CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 371250-54-3 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[3-[(3S)-3-methyl-1-piperazinyl]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 371250-55-4 CAPLUS


CN 4(1H)-Quinolinone, 7-methoxy-2-[3-(4-morpholinylmethyl)phenyl]-6-(5-

oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-56-5 CAPLUS

CN 4 (1H)-Quinolinone, 2-[4-(1-hydroxy-1-methylethyl)phenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-57-6 CAPLUS

CN 4 (1H)-Quinolinone, 2-[4-(hydroxymethyl)phenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-58-7 CAPLUS

CN 4 (1H)-Quinolinone, 7-methoxy-2-[3-[(4-methoxyphenyl)methoxy]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-59-8 CAPLUS

CN 4(1H)-Quinolinone, 2-(3-hydroxyphenyl)-7-methoxy-6-(5-oxazolyl)- (9CI)
(CA INDEX NAME)




RN 371250-60-1 CAPLUS

CN 4(1H)-Quinolinone, 2-[3-[2-(dimethylamino)ethoxy]phenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-61-2 CAPLUS

CN 4(1H)-Quinolinone, 2-(2,3-dihydro-2-methyl-1H-isoindol-5-yl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-62-3 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(4-thiazolyl)- (9CI) (CA INDEX NAME)




RN 371250-63-4 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-[2-(1-piperidiny)-4-thiazolyl]- (9CI) (CA INDEX NAME)




RN 371250-64-5 CAPLUS

CN 4(1H)-Quinolinone, 2-(3,5-dimethylphenyl)-7-methoxy-6-(5-oxazolyl) - (9CI)
(CA INDEX NAME)




RN 371250-65-6 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[3-(methylthio)phenyl]-6-(5-oxazolyl) - (9CI) (CA INDEX NAME)




RN 371250-66-7 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[3-(methylsulfonyl)phenyl]-6-(5-oxazolyl) - (9CI) (CA INDEX NAME)




RN 371250-67-8 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[3-[4-(2-methoxyethyl)-1-piperazinyl]phenyl]-6-(5-oxazolyl) - (9CI) (CA INDEX NAME)




RN 371250-68-9 CAPLUS

CN 4(1H)-Quinolinone, 2-[3-(2,6-dimethyl-4-morpholinyl)phenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-69-0 CAPLUS

CN 4(1H)-Quinolinone, 2-(3-bromo-4-methylphenyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-70-3 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-[3-[[tetrahydro-2-furanyl)methyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 371250-71-4 CAPLUS

CN 4(1H)-Quinolinone, 2-[3-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-72-5 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-(4-morpholinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-73-6 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-(4-methyl-1-piperazinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-74-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2-methylphenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 371250-75-8 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-(1-pyrrolidinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-76-9 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[3-[(2-methoxyethyl)amino]-4-methylphenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-77-0 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[5-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2-methylphenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 371250-78-1 CAPLUS


CN 4(1H)-Quinolinone, 2-[3-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-4-methylphenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371250-79-2 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-(1-piperazinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-80-5 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-(4-thiomorpholinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-81-6 CAPLUS


CN 4(1H)-Quinolinone, 2-(3-bromo-4-methoxyphenyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-82-7 CAPLUS
 CN 4(1H)-Quinolinone, 2-[3-(1,1-dioxido-4-thiomorpholinyl)-4-methylphenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-83-8 CAPLUS
 CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methoxy-3-(4-morpholinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-84-9 CAPLUS
 CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methoxy-3-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371250-85-0 CAPLUS
 CN 4(1H)-Quinolinone, 2-[3-(1-azetidiny)l]-4-methoxyphenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-86-1 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-87-2 CAPLUS


CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methoxy-3-[[2-(methylamino)ethyl]amino]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371250-88-3 CAPLUS


CN 4(1H)-Quinolinone, 2-[3-[(2R)-2-(dimethylamino)-1-pyrrolidinyl]-4-methoxyphenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371250-89-4 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methoxy-3-[(2-methoxyethyl)amino]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-90-7 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methoxy-3-[[2-(4-morpholinyl)ethyl]amino]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-91-8 CAPLUS

CN Benzonitrile, 5-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 371250-92-9 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(5,6,7,8-tetrahydro-8-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 371250-93-0 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(5,6,7,8-tetrahydro-8-hydroxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 371250-94-1 CAPLUS

CN Carbamic acid, dimethyl-, 7-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1,2,3,4-tetrahydro-1-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 371250-95-2 CAPLUS

CN 4(1H)-Quinolinone, 2-[8-(dimethylamino)-5,6,7,8-tetrahydro-2-naphthalenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-96-3 CAPLUS

CN 4(1H)-Quinolinone, 2-ethyl-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371250-97-4 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-[3-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 371250-98-5 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-[4-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 371250-99-6 CAPLUS

CN 4(1H)-Quinolinone, 2-[4-(dimethylamino)-3,4-dihydro-2H-1-benzopyran-6-yl]-
7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-00-2 CAPLUS

CN 4(1H)-Quinolinone, 2-cyclohexyl-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX
NAME)




RN 371251-01-3 CAPLUS

CN 4(1H)-Quinolinone, 2-[3,4-dihydro-4-(1-pyrrolidinyl)-2H-1-benzopyran-6-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-02-4 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-6-(5-oxazolyl)-2-(1-phenylcyclopropyl)- (9CI) (CA INDEX NAME)




RN 371251-03-5 CAPLUS

CN 4(1H)-Quinolinone, 2-(4-bromophenyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-04-6 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[4-(4-methyl-1-piperazinyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-05-7 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[4-(4-morpholinyl)phenyl]-6-(5-oxazolyl)-
(9CI) (CA INDEX NAME)




RN 371251-06-8 CAPLUS

CN Carbamic acid, [6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]methyl-, phenylmethyl ester (9CI)
(CA INDEX NAME)




RN 371251-12-6 CAPLUS

CN 4(1H)-Quinolinone, 2-[2,3-dihydro-3-(methylamino)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-13-7 CAPLUS

CN 4(1H)-Quinolinone, 2-[2,3-dihydro-3-(1-pyrrolidinyl)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-16-0 CAPLUS

CN 4(1H)-Quinolinone, 2-[2,3-dihydro-3-(4-morpholinyl)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-19-3 CAPLUS

CN 4(1H)-Quinolinone, 2-[3-(1-azetidiny)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-21-7 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[(3-methylphenyl)methyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-29-5 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-36-4 CAPLUS

CN 4(1H)-Quinolinone, 3-hydroxy-7-methoxy-6-(5-oxazolyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 371251-40-0 CAPLUS

CN 4(1H)-Quinolinone, 3-hydroxy-7-methoxy-2-(2-methylphenyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-41-1 CAPLUS

CN 4(1H)-Quinolinone, 3-hydroxy-7-methoxy-2-(3-methylphenyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-42-2 CAPLUS

CN 4(1H)-Quinolinone, 3-hydroxy-7-methoxy-2-(4-methylphenyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-43-3 CAPLUS

CN 4(1H)-Quinolinone, 2-(3,4-dimethylphenyl)-3-hydroxy-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-44-4 CAPLUS

CN 4(1H)-Quinolinone, 3-hydroxy-7-methoxy-2-(4-methoxyphenyl)-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-45-5 CAPLUS

CN 4(1H)-Quinolinone, 2-(4-chloro-3-methylphenyl)-3-hydroxy-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-47-7 CAPLUS

CN 4(1H)-Quinolinone, 2-(4-chloro-3-methylphenyl)-3-hydroxy-7-methoxy-6-(5-

06/02/2003


09840503.trn

oxazolyl)-, trifluoroacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 371251-45-5


CMF C20 H15 Cl N2 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 371251-48-8 CAPLUS

CN 4(1H)-Quinolinone, 2-(2,3-dihydro-3-methoxy-1H-inden-5-yl)-3-hydroxy-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-50-2 CAPLUS

CN 4(1H)-Quinolinone, 3-hydroxy-7-methoxy-2-[2-(methylsulfonyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-51-3 CAPLUS

CN 4(1H)-Quinolinone, 2-[1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-53-5 CAPLUS

CN 4(1H)-Quinolinone, 2-(2,3-dihydro-3-methoxy-2,2-dimethyl-1H-inden-5-yl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-55-7 CAPLUS

CN 4(1H)-Quinolinone, 2-(2,3-dihydro-3-methoxy-1,1-dimethyl-1H-inden-5-yl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-57-9 CAPLUS

CN 4(1H)-Quinolinone, 2-[(2R,3R)-3-(dimethylamino)-2,3-dihydro-2-methoxy-1H-

inden-5-yl]-7-methoxy-6-(5-oxazolyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 371251-60-4 CAPLUS

CN 4(1H)-Quinolinone, 2-[(2R,3R)-3-(dimethylamino)-2,3-dihydro-2-hydroxy-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 371251-61-5 CAPLUS

CN 4(1H)-Quinolinone, 2-[(2R,3R)-3-(dimethylamino)-2,3-dihydro-2-[[[(methylamino)carbonyl]oxy]-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 371251-62-6 CAPLUS

CN Carbamic acid, ethyl-, (1R,2R)-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 371251-63-7 CAPLUS

CN Carbamic acid, (1-methylethyl)-, (1R,2R)-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 371251-64-8 CAPLUS

CN Carbamic acid, (2-chloroethyl)-, (1R,2R)-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 371251-65-9 CAPLUS


CN Imidodicarbonic acid, (1R,2R)-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-1-(dimethylamino)-2,3-dihydro-1H-inden-2-yl methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 371251-66-0 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-(phenylmethoxy)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-68-2 CAPLUS

CN 4(1H)-Quinolinone, 2-(3-hydroxy-4-methylphenyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-70-6 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[3-(2-methoxyethoxy)-4-methylphenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-72-8 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-73-9 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-[2-(4-morpholinyl)ethoxy]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-74-0 CAPLUS

CN 4(1H)-Quinolinone, 2-[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methylphenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-75-1 CAPLUS

CN 4(1H)-Quinolinone, 2-[3-[2-(dimethylamino)ethoxy]-4-methylphenyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-76-2 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-[(tetrahydro-3-furanyl)methoxy]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-77-3 CAPLUS


CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-[(1-methyl-4-piperidinyloxy]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 371251-78-4 CAPLUS


CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-[(2S)-1-methyl-2-pyrrolidinylmethoxy]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 371251-79-5 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-80-8 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-[2-(2-pyridinyl)ethoxy]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-81-9 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[4-methyl-3-[(tetrahydro-2-furanyl)methoxy]phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-82-0 CAPLUS

CN 1H-Inden-1-aminium, 6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-N,N,N-trimethyl- (9CI) (CA INDEX NAME)




RN 371251-83-1 CAPLUS

CN 4(1H)-Quinolinone, 2-[3-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-3-hydroxy-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-86-4 CAPLUS

CN 6-Quinolinecarbonitrile, 1,4-dihydro-3-hydroxy-7-methoxy-2-(4-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 371251-88-6 CAPLUS

CN 6-Quinolinecarbonitrile, 1,4-dihydro-3-hydroxy-7-methoxy-2-(3-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 371251-92-2 CAPLUS

CN 4(1H)-Quinolinone, 2-(2,3-dihydro-3-hydroxy-1H-inden-5-yl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-94-4 CAPLUS

CN 4(1H)-Quinolinone, 2-(3,4-dimethoxyphenyl)-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371251-97-7 CAPLUS

CN 4(1H)-Quinolinone, 2-[5-[(dimethylamino)methyl]-3-thienyl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371252-06-1 CAPLUS

CN Carbamic acid, [6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 371252-09-4 CAPLUS

CN Acetamide, N-[6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 371252-11-8 CAPLUS

CN Acetamide, N-[6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 371252-12-9 CAPLUS

CN 1H-Imidazole-1-acetamide, N-[6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 371252-13-0 CAPLUS

CN 4-Morpholineacetamide, N-[6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 371252-14-1 CAPLUS

CN 2H-1,2,3-Triazole-2-acetamide, N-[6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 371252-15-2 CAPLUS

CN 1H-1,2,3-Triazole-1-acetamide, N-[6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 371252-16-3 CAPLUS

CN Carbamic acid, [6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl]methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 371252-17-4 CAPLUS

CN Carbamic acid, dimethyl-, 6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-1H-inden-1-yl ester (9CI) (CA INDEX NAME)




RN 371252-18-5 CAPLUS

CN 4(1H)-Quinolinone, 2-[2,3-dihydro-1-(1-pyrrolidinyl)-1H-inden-5-yl]-7-methoxy-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371252-19-6 CAPLUS

CN 2H-1,4-Benzoxazine, 4-acetyl-6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 371252-21-0 CAPLUS

CN 4(1H)-Quinolinone, 7-methoxy-2-[4-(4-morpholinylmethyl)phenyl]-6-(5-oxazolyl)- (9CI) (CA INDEX NAME)




RN 371252-22-1 CAPLUS

CN 1H-Inden-1-aminium, 6-[1,4-dihydro-7-methoxy-6-(5-oxazolyl)-4-oxo-2-quinolinyl]-2,3-dihydro-N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)




● I⁻

L8 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2003 ACS
GI



I



II

AB Title compds. I [R1 = alkyl, cycloalkyl, Ph, alkoxy, halo, NO2, NH2, (un)substituted heterocyclyl, etc.; n = 1, 2, 3; R2 = alkyl, (un)substituted Ph, heterocyclyl, etc.; R3 = H, alkyl, Ph, alkoxy, CN, etc.; R2R3 = fused ring system; R4 = alkyl, alkenyl, benzyl, (un)substituted phenyl] were prepd. as antiviral agents. Thus, II (R4 = H) was prepd. in 81% yield by reaction of 4-isopropylaniline with Et 2-benzoylpropionate in EtOH contg. polyphosphoric acid at 160.degree., and subsequent ethylation by EtI in the presence of K2CO3 in DMF gave II (R4 = Et). I were tested against picornaviruses, rhinoviruses, and rotaviruses.

ACCESSION NUMBER: 2001:167663 CAPLUS
DOCUMENT NUMBER: 134:207726
TITLE: 1,2-Disubstituted 1,4-dihydro-4-oxoquinoline compounds and their antiviral activity
INVENTOR(S): Tamura, Takashi; Kuriyama, Haruo; Agoh, Masanobu; Agoh, Yumi; Soga, Manabu; Mori, Teruyo
PATENT ASSIGNEE(S): Maruishi Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 64 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1081138	A1	20010307	EP 2000-118673	20000829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001064259	A2	20010313	JP 1999-242700	19990830
JP 2001064261	A2	20010313	JP 1999-242701	19990830
JP 3259089	B2	20020218		
JP 2001089455	A2	20010403	JP 1999-262883	19990917
JP 2001089476	A2	20010403	JP 1999-262884	19990917
US 6541470	B1	20030401	US 2000-649596	20000829
PRIORITY APPLN. INFO.:			JP 1999-242700	A 19990830
			JP 1999-242701	A 19990830
			JP 1999-262883	A 19990917
			JP 1999-262884	A 19990917

OTHER SOURCE(S): MARPAT 134:207726

IT 328398-76-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(1,2-disubstituted 1,4-dihydro-4-oxoquinolines as antiviral agents)

RN 328398-76-1 CAPLUS

CN 4(1H)-Quinolinone, 1-methyl-2-phenyl-6-(3-pyridinyl)- (9CI) (CA INDEX

NAME)

prints

REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

To: Laurelee Duncan faxed on 6/3/03

06/02/2003


09840503.trn

L8 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2003 ACS
GI For diagram(s), see printed CA Issue.
AB Quinolinyl ketones I [A = II, III; X = NH, O, S; B = (substituted) arom.; R2 = H, halo, lower (halo)alkyl, (hetero atom-contg.) cycloalkyl, (substituted) aryl, etc.; R3 = H, halo, lower (halo)alkyl, (hetero atom-contg.) cycloalkyl, alkoxyalkyl, (substituted) aryl, etc.; R2 and R3 may form (N-, O-, or S-contg.) (substituted) ring.; R1 = CR4R5R6; R4, R5 = H, lower (halo)alkyl, (hetero atom-contg.) cycloalkyl, lower (halo)alkyloxy, etc.; R4 and R5 may form (N-, O-, or S-contg.) (substituted) ring.; R6 = H, lower (halo)alkyl, (hetero atom-contg.) cycloalkyl, (substituted) (hetero)aryl, etc.] and IV (A, B, X, R2, R3 = same as I) or their pharmaceutically acceptable salts, useful as inhibitors of interleukin-1 prodn., are prepd. 7-Ethyl-4-methoxymethoxy-3,5,8-trimethoxy-2-quinolinecarboxaldehyde (prepn. given) was condensed with MeCOCMe(OH)Me in MeOH in the presence of LiOH.H2O at 50-60.degree. for 1 h and deprotected with HCl in AcOEt at room temp. for 10 min to give 71% I (A = 1,4-dihydro-7-ethyl-4-oxo-3,5,8-trimethoxyquinolinyl, R1 = CMe2OH) (V). V in vitro showed IC50 of 1.08 and 0.92 .mu.M against IL-.alpha. and IL-.beta. resp.

ACCESSION NUMBER: 1997:765311 CAPLUS
DOCUMENT NUMBER: 128:88793
TITLE: Preparation of .alpha.,.beta.-unsaturated quinolinyl ketones as inhibitors of interleukin-1 production
INVENTOR(S): Tanaka, Masayuki; Okita, Makoto; Miyamoto, Mitsuaki; Kaneko, Toshihiko; Kawahara, Tetsuya; Akamatsu, Keiji; Chiba, Kenichi; Obaishi, Hiroshi; Sakurai, Hideki; Abe, Shinya; Kobayashi, Kiyokazu; Yamanaka, Teiji
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 116 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09309879	A2	19971202	JP 1996-148569	19960520
PRIORITY APPLN. INFO.:			JP 1996-148569	19960520
OTHER SOURCE(S):	MARPAT 128:88793			

IT 185206-37-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinolinyl ketones as inhibitors of interleukin-1 prodn.)
RN 185206-37-5 CAPLUS
CN 6-Quinolinecarbonitrile, 1,4-dihydro-3-methyl-4-oxo-2-(3-oxo-1-butenyl)-(9CI) (CA INDEX NAME)





06/02/2003

09840503.trn

8

L8 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2003 ACS
GI



AB Trifluoroacetamido derivs. I (Q = O; R = Br, I; X = CN, CO₂Et, NO₂) react with phosphorane Ph₃P:CHCO₂Et in boiling toluene to give the corresponding enamines I (Q = CHCO₂Et; same R, X), which are precursors of the trifluoromethylated indoles II and quinolones III.

ACCESSION NUMBER: 1997:520074 CAPLUS

DOCUMENT NUMBER: 127:205460

TITLE: Synthesis of indoles and quinolones by sequential Wittig and Heck reactions

AUTHOR(S): Latham, Elliot J.; Stanforth, Stephen P.

CORPORATE SOURCE: Department of Chemical and Life Sciences, University of Northumbria at Newcastle, Newcastle upon Tyne, NE1 8ST, UK

SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1997), (14), 2059-2063

CODEN: JCPRB4; ISSN: 0300-922X

PUBLISHER: Royal Society of Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 127:205460

IT 183989-99-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of indoles and quinolones by sequential Wittig and Heck reactions)

RN 183989-99-3 CAPLUS

CN 3-Quinolinecarboxylic acid, 6-cyano-1,4-dihydro-4-oxo-2-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2003 ACS
 GI For diagram(s), see printed CA Issue.
 AB .alpha.,.beta.-Unsatd. ketone derivs. represented by general formula
 RCH:CHCOR1 [R = Q, Q1; wherein Z = NH, O, S; ring B = an optionally
 substituted arom. ring; R2 = H, halo, optionally halogenated lower alkyl,
 etc.; R3 = H, optionally halogenated lower alkyl, cycloalkyl optionally
 having heteroatom(s), alkoxyalkyl, optionally substituted aryl, optionally
 substituted heteroaryl, etc.; R1 = CR4R5R6; wherein R4, R5 = H, optionally
 halogenated lower alkyl, etc.; R6 = H, optionally halogenated lower alkyl,
 cycloalkyl optionally having heteroatom(s), optionally substituted aryl,
 optionally substituted heteroaryl, etc.] or pharmacol. acceptable salts
 thereof, which are useful for the prevention and treatment of interleukin
 1 prodn.-related diseases, e.g. inflammation, are prepd. Thus, 1.68 g
 7-ethyl-4-methoxymethoxy-3,5,8-trimethoxy-2-quinolinecarboxaldehyde and
 1.0 g 3-hydroxy-3-methyl-2-butanone were dissolved in MeOH, treated with
 0.21 g LiOH.H2O and heated at 50-60.degree. for 1 h to give, after
 treatment of the product with 1 N aq. HCl in EtOAc, the title
 quinolinylbutenone deriv. (I; R7 = R10 = OMe, R8 = H, R9 = Et, R11 =
 CMe2OH). The latter compd. and I (R7 = R9 = R10 = H, R8 = Cl, R2 = R11 =
 Me) showed IC50 of 1.08 and <0.1 nM, resp., for inhibiting the prodn. of
 interleukin 1.alpha. in human peripheral monocyte and 0.92 and <0.1 nM,
 resp., for inhibiting the prodn. of interleukin 1.beta. in human
 peripheral monocyte.


ACCESSION NUMBER: 1997:41948 CAPLUS
 DOCUMENT NUMBER: 126:59875
 TITLE: Preparation of beta-heterocyclyl-alpha,
 beta-unsaturated ketone derivatives as inhibitors of
 interleukin 1 production
 INVENTOR(S): Tanaka, Masayuki; Okita, Makoto; Miyamoto, Mitsuaki;
 Kaneko, Toshihiko; Kawahara, Tetsuya; Akamatsu,
 Keishi; Chiba, Kenichi; Obaishi, Hiroshi; Sakurai,
 Hideki; Abe, Shinya; Kobayashi, Seiichi; Yamanaka,
 Takashi
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan; Tanaka, Masayuki; Okita,
 Makoto; Miyamoto, Mitsuaki; Kaneko, Toshihiko;
 Kawahara, Tetsuya; Akamatsu, Keishi; Chiba, Kenichi;
 Obaishi, Hiroshi; et al.
 SOURCE: PCT Int. Appl., 254 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9636608	A1	19961121	WO 1996-JP1330	19960520
W: CA, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 08311032	A2	19961126	JP 1995-142394	19950518
PRIORITY APPLN. INFO.:			JP 1995-142394	19950518
OTHER SOURCE(S): MARPAT 126:59875				
IT 185204-09-5P 185206-37-5P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(prepn. of .beta.-heterocyclyl-.alpha., .beta.-unsatd. ketone derivs. as inhibitors of interleukin 1 prodn.)				
RN 185204-09-5 CAPLUS				
CN 6-Quinolinecarbonitrile, 1,4-dihydro-2-(4-hydroxy-4-methyl-3-oxo-1-				

06/02/2003


09840503.trn

pentenyl)-3-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 185206-37-5 CAPLUS

CN 6-Quinolinecarbonitrile, 1,4-dihydro-3-methyl-4-oxo-2-(3-oxo-1-butenyl)-
(9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2003 ACS
GI



AB N-trifluoroacetylanilines I (R = Br, iodo, X = cyano, CO₂Et, NO₂) undergo a Wittig reaction with phosphorane Ph₂P:CHCO₂Et giving enamine derivs. II which are precursors to indoles III and quinolines IV.

ACCESSION NUMBER: 1996:633861 CAPLUS

DOCUMENT NUMBER: 126:18764

TITLE: Synthesis of indoles and quinolones by sequential Wittig and Heck reactions

AUTHOR(S): Latham, Elliot J.; Stanforth, Stephen P.

CORPORATE SOURCE: Dep. Chem., Life Science, Univ. Northumbria Newcastle, Newcastle upon Tyne, NE1 8ST, UK

SOURCE: Chemical Communications (Cambridge) (1996), (19), 2253-2254

CODEN: CHCOFS; ISSN: 1359-7345

PUBLISHER: Royal Society of Chemistry

DOCUMENT TYPE: Journal


LANGUAGE: English

IT 183989-99-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of indoles and quinolines by Wittig-Heck reaction of
(trifluoroacetyl)anilines)


RN 183989-99-3 CAPLUS

CN 3-Quinolinecarboxylic acid, 6-cyano-1,4-dihydro-4-oxo-2-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



same as previous

L8 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2003 ACS
GI



AB A novel series of title compds. was prepd. When evaluated in an in vitro binding assay using a guinea pig adrenal membrane prepn., compds. in this series generally gave ED50 values in the range 0.01-1 .mu.M. Structure-activity studies showed the quinoline N atom and a short alkyl chain at the quinoline 2-position to be essential for receptor binding. At 1-10 mg/kg in AII-infused, normotensive rats, the title compd. I exhibited a dose-related inhibition of the pressor response with a good duration of action at the higher doses. In a renal hypertensive rat model, I showed a rapid and sustained lowering of blood pressure at a dose of 5 mg/kg.

ACCESSION NUMBER: 1992:612398 CAPLUS

DOCUMENT NUMBER: 117:212398

TITLE: New nonpeptide angiotensin II receptor antagonists.

2. Synthesis, biological properties, and structure-activity relationships of

2-alkyl-4-(biphenylmethoxy)quinoline derivatives

AUTHOR(S): Bradbury, Robert H.; Allott, Christopher P.; Dennis, Michael; Fisher, Eric; Major, John S.; Masek, Brian B.; Oldham, Alec A.; Pearce, Robert J.; Rankine, Neil; et al.

CORPORATE SOURCE: Dep. Chem., ICI Pharm., Macclesfield/Cheshire, SK10 4TG, UK

SOURCE: Journal of Medicinal Chemistry (1992), 35(22), 4027-38
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal


LANGUAGE: English

IT 135016-07-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and enol alkylation of)


RN 135016-07-8 CAPLUS

CN 6-Quinolinecarbonitrile, 2-ethyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



Intermediate

L8 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2003 ACS
GI



AB Modifications to the bicyclic ring system of the potent thymidylate synthase (TS) inhibitor N-[4-[N-[(2-amino-3,4-dihydro-4-oxo-6-quinazolinyl)methyl]-N-prop-2-ynylamino]benzoyl]-L-glutamic acid (CB3717) have led to the synthesis of a series of quinoline antifolates, e.g., I (R¹ = Me, CH₂OH, CF₃; R² = H, MeO, Me, cyano, Cl; R³ = HC.tplbond.CCH₂, H, Et; R⁴ = H, F), bearing a variety of substituents at the C2 and C4 positions. In general the synthetic route involved the coupling of the appropriate di-Et N-[4-(prop-2-ynylamino)benzoyl]-L-glutamate II with a disubstituted 6-(bromomethyl)quinoline III followed by deprotection using mild alkali. The compds. were tested as inhibitors of partially purified L1210 TS. As a measure of cytotoxicity, the compds. were tested for their inhibition of the growth of L1210 cells in culture. Good enzyme inhibition and cytotoxicity were found for compds. contg. chloro, amino, or Me substituents at the C2 position with chloro or bromo substituents at C4. The effect on enzyme inhibition of varying the N10 substituent of I (R¹ = Me, R² = Cl, R³ = HC.tplbond.CCH₂, R⁴ = H) was similar to that obsd. in the quinazolinone-contg. antifolates, indicating that the quinoline compds. may be interacting with the enzyme in a similar way to the quinazolinones. Also, the introduction of a 2'-fluoro substituent into the benzoyl ring of several of the quinoline antifolates, e.g., I (R¹ = Cl, R² = Cl, R³ = HC.tplbond.CCH₂, R⁴ = F), led to a increase in both TS inhibition and the inhibition of L1210 cell growth. These data demonstrate that the N3-H of the pyrimidine ring of the quinazolinone antifolates is not required for binding to TS if appropriate substituents are placed at the C2 and C4 positions of the bicyclic ring system.

ACCESSION NUMBER: 1992:469707 CAPLUS
DOCUMENT NUMBER: 117:69707
TITLE: Quinoline antifolate thymidylate synthase inhibitors: variation of the C2- and C4-substituents
AUTHOR(S): Warner, Peter; Barker, Andrew J.; Jackman, Ann L.; Burrows, Kenneth D.; Roberts, Neal; Bishop, Joel A. M.; O'Connor, Brigid M.; Hughes, Leslie R.
CORPORATE SOURCE: Dep. Chem., ICI Pharm., Macclesfield/Cheshire, SK10 4TG, UK
SOURCE: Journal of Medicinal Chemistry (1992), 35(15), 2761-8
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 123638-03-9
RL: RCT (Reactant); RACT (Reactant or reagent)


06/02/2003

09840503.trn

(redn. of)

RN 123638-03-9 CAPLUS



CN 6-Quinolinecarbonitrile, 1,4-dihydro-2-methyl-4-oxo- (9CI) (CA INDEX
NAME)



same

intermediate

L8 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2003 ACS
GI



AB Title compds. I (R1 = H, alkyl, cycloalkyl, Ph, substituted alkyl; R2 = H, alkyl, cycloalkyl, HO2C, NC, O2N, Ph, phenylalkyl; R3, R4 = H, alkyl, alkoxy, fluoroalkoxy, halo, HO, F3C, NC, O2N, H2O, etc. R3R4 = C1-4 alkylenedioxy attached to adjacent C; R, R5 = H, alkyl, alkoxy, halo, F3C, NC, O2N; X = substituted C6H4, bond; Z = 1-tetrazol-5-yl, etc.) or salts thereof, useful for treatment of hypertension and congestive heart failure, are prepd. 2-Methyl-4-(2-(2-triphenylmethyl-2H-tetrazol-5-yl)biphenyl-4-yl)methoxyquinoline (prepn. from 2-methyl-4-quinolone and the corresponding bromomethylbiphenyl given), dioxane.HCl and H2O were kept for 72 h to give title compd. II.HCl (III). In tests for antagonizing angiotensin II in vitro and in vivo, III showed IC50 1.7 .times. 1--8M, pA2 8.95, and ED50 of 0.5 mg/kg, i.v. In addn. I demonstrated a significant redn. in blood pressure at 50 mg/kg or less, without any overt toxicol. or other unsatd. pharmacol. effects. A large no. of I and intermediates were prepd. Pharmaceutical formulations comprising I are given.

ACCESSION NUMBER: 1991:471607 CAPLUS

DOCUMENT NUMBER: 115:71607

TITLE: Preparation of arylmethoxyquinolines
(tetrazolylbiphenylmethoxyquinolines) as
cardiovascular agents.

INVENTOR(S): Roberts, David Anthony; Russell, Simon Thomas; Pearce,
Robert James

PATENT ASSIGNEE(S): Imperial Chemical Industries PLC, UK

SOURCE: Eur. Pat. Appl., 33 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 412848	A2	19910213	EP 1990-308855	19900810

EP 412848	A3	19910410		
EP 412848	B1	19950118		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2023229	AA	19910212	CA 1990-2023229	19900802
NO 9003525	A	19910212	NO 1990-3525	19900810
GB 2234748	A1	19910213	GB 1990-17616	19900810
GB 2234748	B2	19930630		
AU 9060955	A1	19910214	AU 1990-60955	19900810
AU 623546	B2	19920514		
ZA 9006358	A	19910424	ZA 1990-6358	19900810
HU 54991	A2	19910429	HU 1990-4961	19900810
DD 298922	A5	19920319	DD 1990-343371	19900810
CN 1050187	A	19910327	CN 1990-106923	19900811
JP 03169863	A2	19910723	JP 1990-214223	19900813
JP 3010056	B2	20000214		
US 5444071	A	19950822	US 1993-58825	19930504

PRIORITY APPLN. INFO.:

GB 1989-18402	A	19890811
GB 1990-3187	A	19900213
US 1990-565764	B1	19900810


OTHER SOURCE(S): MARPAT 115:71607

IT 123638-03-9P 135016-07-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. and reaction of, in prepn. of cardiovascular agent)


RN 123638-03-9 CAPLUS

CN 6-Quinolinecarbonitrile, 1,4-dihydro-2-methyl-4-oxo- (9CI) (CA INDEX NAME)

*intermediates*

RN 135016-07-8 CAPLUS

CN 6-Quinolinecarbonitrile, 2-ethyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



IT 135016-07-8


RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of arylmethoxyquinoline cardiovascular agent)

RN 135016-07-8 CAPLUS

CN 6-Quinolinecarbonitrile, 2-ethyl-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

06/02/2003

09840503.trn




RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of cardiovascular agent

L8 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2003 ACS
 GI For diagram(s), see printed CA Issue.
 AB Title compds. I [R1, R2 = H, halo, OH, cyano, carbamoyl, NO2, NH2, alkyl, etc.; both R1, R2 .noteq. H; R3 = H, (substituted) alkyl; R4 = H, alkyl, alkenyl, alkynyl; Z = C6H4, naphthalene, heterocyclylene; the above groups may be substituted; R5NH = amino acid residue; X = halo, OH, cyano, alkyl, etc.; n = 0-2], useful as antitumor agents (no data), are prepd. from II (Y = leaving group, NR4ZCO2H). A mixt. of II (R1 = Me; R2 = Cl; R3 = Xn = H; Y = Br) (prepn. given), di-Et N-[2-fluoro-4-(prop-2-ynyl)aminobenzoyl]-L-glutamate, 2,6-lutidine, and DMF was heated at 70.degree., followed by sapon. of the resultant ester and acidification to give N-[4-[N-(4-chloro-2-methylquinolin-6-ylmethyl)-N-(prop-2-ynyl)amino]-2-fluorobenzoyl]-L-glutamic acid.

ACCESSION NUMBER: 1989:614940 CAPLUS
 DOCUMENT NUMBER: 111:214940
 TITLE: N-(quinolinylmethylaminoarylcarbonyl)amino acids as antitumor agents
 INVENTOR(S): Burrows, Kenneth David; Hughes, Leslie Richard; Warner, Peter
 PATENT ASSIGNEE(S): Imperial Chemical Industries PLC, UK; National Research and Development Corp.
 SOURCE: Eur. Pat. Appl., 34 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 318225	A2	19890531	EP 1988-310972	19881121
EP 318225	A3	19901205		
EP 318225	B1	19940316		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 01258664	A2	19891016	JP 1988-296396	19881125
US 5112837	A	19920512	US 1990-584489	19900917
PRIORITY APPLN. INFO.:			GB 1987-27737	19871126
			US 1988-271271	19881115
OTHER SOURCE(S):			MARPAT 111:214940	
IT 123638-03-9				
RL: RCT (Reactant); RACT (Reactant or reagent) (reaction of, in prepn. of antitumor agents)				
RN 123638-03-9 CAPLUS				
CN 6-Quinolinecarbonitrile, 1,4-dihydro-2-methyl-4-oxo- (9CI) (CA INDEX NAME)				



Intermediates

06/02/2003

09840503.trn

=> d his

(FILE 'HOME' ENTERED AT 14:22:01 ON 02 JUN 2003)

FILE 'REGISTRY' ENTERED AT 14:22:13 ON 02 JUN 2003

L1 STRUCTURE UPLOADED
L2 234 S L1 FUL

FILE 'CAPLUS' ENTERED AT 14:22:50 ON 02 JUN 2003

L3 30 S L2

FILE 'REGISTRY' ENTERED AT 14:24:49 ON 02 JUN 2003

L4 STRUCTURE UPLOADED
L5 1 S L1
L6 1 S L4
L7 200 S L4 FUL SUB=L2

FILE 'CAPLUS' ENTERED AT 14:25:48 ON 02 JUN 2003

L8 11 S L7

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

50.31

235.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION



CA SUBSCRIBER PRICE

-7.16

-7.16

STN INTERNATIONAL LOGOFF AT 14:26:20 ON 02 JUN 2003

structure search after amendment.



chain nodes :

11 14 16

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

3-16 7-11 9-14

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :

3-16 5-7 6-10 7-8 7-11 8-9 9-10 9-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :


containing 1 :

G1:CN,Hy


G2:C,Cy

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
14:CLASS 16:CLASS



Hy^e 1



17^e 1

```
chain nodes :
  11 14 16 17
ring nodes :
  1 2 3 4 5 6 7 8 9 10
chain bonds :
  3-16 7-11 9-14
ring bonds :
  1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
  3-16 5-7 6-10 7-8 7-11 8-9 9-10 9-14
normalized bonds :
  1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
  containing 1 :
```

G1:CN,[*1]

G2:C,Cy

```
Match level :
  1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
  14:CLASS 16:CLASS 17:Atom
Generic attributes :
  17:
  Saturation      : Unsaturated
  Type of Ring System : Monocyclic
```